NCL foundation together with Evotec and Hamburg University explores new paths in juvenile NCL


Hamburg, Germany, 22 October 2018:
NCL foundation announces today that together with the biotechnology Company Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) it supports a three-year PhD programme for research into juvenile neuronal ceroid lipofuscinosis (NCL). Under scientific supervision by Dr Guido Hermey (Hamburg University), the PhD programme will be based in the facilities and laboratories of Evotec AG. 

The full version of this press release is available in German only. For the German version of the release, please follow this link.